Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.4
5.2
Journals
Cancers
Special Issues
Microenvironment of Leukemia
share announcement

Microenvironment of Leukemia

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Tumor Microenvironment".

Deadline for manuscript submissions: 20 September 2024 | Viewed by 6168

Special Issue Editor

Dr. Francesco Bertolini

E-Mail Website
Guest Editor
European Institute of Oncology, Milan, Italy
Interests: hemato-oncology

Special Issue Information

Dear Colleagues,

Unbalanced nursing signals from the stromal microenvironment to cells affected by genetic and epigenetic alterations with neoplastic potential are known to be crucial hallmarks of the very large majority of solid cancer types. Emerging recent evidence indicates that, also in circulating neoplastic diseases such as chronic and acute leukemias, an altered cross-talk between microenvironment niches in the bone marrow and some other hematopoietic reservoirs may be needed to support the expansion of early neoplastic clones. These findings might have profound implications for the diagnosis and treatment of leukemias, and are opening new fields for basic, translational and clinical studies. This Special Issue of Cancers offers a discussion platform for scientists and clinicians interested in this emerging topic.

I am pleased to invite you to contribute to this Special Issue. Original research articles and review articles are welcome.

We are looking forward to receiving your contributions.

Dr. Francesco Bertolini
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • stromal microenvironment
  • genetic and epigenetic alterations
  • bone marrow
  • chronic and acute leukemia
  • hematological malignancies

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

15 pages, 2180 KiB  
Article
Bone Marrow Microenvironment-Induced Chemoprotection in KMT2A Rearranged Pediatric AML Is Overcome by Azacitidine–Panobinostat Combination
by Kara M. Lehner, Anilkumar Gopalakrishnapillai, Edward Anders Kolb and Sonali P. Barwe
Cancers 2023, 15(12), 3112; https://doi.org/10.3390/cancers15123112 - 08 Jun 2023
Cited by 1 | Viewed by 1444
Abstract
Advances in therapies of pediatric acute myeloid leukemia (AML) have been minimal in recent decades. Although 82% of patients will have an initial remission after intensive therapy, approximately 40% will relapse. KMT2A is the most common chromosomal translocation in AML and has a [...] Read more.
Advances in therapies of pediatric acute myeloid leukemia (AML) have been minimal in recent decades. Although 82% of patients will have an initial remission after intensive therapy, approximately 40% will relapse. KMT2A is the most common chromosomal translocation in AML and has a poor prognosis resulting in high relapse rates and low chemotherapy efficacy. Novel targeted approaches are needed to increase sensitivity to chemotherapy. Recent studies have shown how interactions within the bone marrow (BM) microenvironment help AML cells evade chemotherapy and contribute to relapse by promoting leukemic blast survival. This study investigates how DNA hypomethylating agent azacitidine and histone deacetylase inhibitor panobinostat synergistically overcome BM niche-induced chemoprotection modulated by stromal, endothelial, and mesenchymal stem cells and the extracellular matrix (ECM). We show that direct contact between AML cells and BM components mediates chemoprotection. We demonstrate that azacitidine and panobinostat synergistically sensitize MV4;11 cells and KMT2A rearranged pediatric patient-derived xenograft lines to cytarabine in multicell coculture. Treatment with the epigenetic drug combination reduced leukemic cell association with multicell monolayer and ECM in vitro and increased mobilization of leukemic cells from the BM in vivo. Finally, we show that pretreatment with the epigenetic drug combination improves the efficacy of chemotherapy in vivo. Full article
(This article belongs to the Special Issue Microenvironment of Leukemia)
►▼ Show Figures

Figure 1

Review

Jump to: Research

22 pages, 1913 KiB  
Review
The Role of CXCR1, CXCR2, CXCR3, CXCR5, and CXCR6 Ligands in Molecular Cancer Processes and Clinical Aspects of Acute Myeloid Leukemia (AML)
by Jan Korbecki, Patrycja Kupnicka, Katarzyna Barczak, Mateusz Bosiacki, Paweł Ziętek, Dariusz Chlubek and Irena Baranowska-Bosiacka
Cancers 2023, 15(18), 4555; https://doi.org/10.3390/cancers15184555 - 14 Sep 2023
Cited by 2 | Viewed by 1596
Abstract
Acute myeloid leukemia (AML) is a type of leukemia known for its unfavorable prognoses, prompting research efforts to discover new therapeutic targets. One area of investigation involves examining extracellular factors, particularly CXC chemokines. While CXCL12 (SDF-1) and its receptor CXCR4 have been extensively [...] Read more.
Acute myeloid leukemia (AML) is a type of leukemia known for its unfavorable prognoses, prompting research efforts to discover new therapeutic targets. One area of investigation involves examining extracellular factors, particularly CXC chemokines. While CXCL12 (SDF-1) and its receptor CXCR4 have been extensively studied, research on other CXC chemokine axes in AML is less developed. This study aims to bridge that gap by providing an overview of the significance of CXC chemokines other than CXCL12 (CXCR1, CXCR2, CXCR3, CXCR5, and CXCR6 ligands and CXCL14 and CXCL17) in AML’s oncogenic processes. We explore the roles of all CXC chemokines other than CXCL12, in particular CXCL1 (Gro-α), CXCL8 (IL-8), CXCL10 (IP-10), and CXCL11 (I-TAC) in AML tumor processes, including their impact on AML cell proliferation, bone marrow angiogenesis, interaction with non-leukemic cells like MSCs and osteoblasts, and their clinical relevance. We delve into how they influence prognosis, association with extramedullary AML, induction of chemoresistance, effects on bone marrow microvessel density, and their connection to French–American–British (FAB) classification and FLT3 gene mutations. Full article
(This article belongs to the Special Issue Microenvironment of Leukemia)
►▼ Show Figures

Figure 1

26 pages, 2463 KiB  
Review
Acute Lymphoblastic Leukemia Immunotherapy Treatment: Now, Next, and Beyond
by Anna Aureli, Beatrice Marziani, Adriano Venditti, Tommaso Sconocchia and Giuseppe Sconocchia
Cancers 2023, 15(13), 3346; https://doi.org/10.3390/cancers15133346 - 26 Jun 2023
Cited by 4 | Viewed by 2568
Abstract
Acute lymphoblastic leukemia (ALL) is a blood cancer that primarily affects children but also adults. It is due to the malignant proliferation of lymphoid precursor cells that invade the bone marrow and can spread to extramedullary sites. ALL is divided into B cell [...] Read more.
Acute lymphoblastic leukemia (ALL) is a blood cancer that primarily affects children but also adults. It is due to the malignant proliferation of lymphoid precursor cells that invade the bone marrow and can spread to extramedullary sites. ALL is divided into B cell (85%) and T cell lineages (10 to 15%); rare cases are associated with the natural killer (NK) cell lineage (<1%). To date, the survival rate in children with ALL is excellent while in adults continues to be poor. Despite the therapeutic progress, there are subsets of patients that still have high relapse rates after chemotherapy or hematopoietic stem cell transplantation (HSCT) and an unsatisfactory cure rate. Hence, the identification of more effective and safer therapy choices represents a primary issue. In this review, we will discuss novel therapeutic options including bispecific antibodies, antibody–drug conjugates, chimeric antigen receptor (CAR)-based therapies, and other promising treatments for both pediatric and adult patients. Full article
(This article belongs to the Special Issue Microenvironment of Leukemia)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3

Planned Papers

The below list represents only planned manuscripts. Some of these manuscripts have not been received by the Editorial Office yet. Papers submitted to MDPI journals are subject to peer-review.

Title: a review on the mechanisms of anti leukemia effect and escape of NK cells
Authors: Stéphanie Nguyen-Quoc
Affiliation: Francophone Society of Stem Cell Transplantation and Cellular Therapy (SFGM-TC), Paris, France

Title: a review on the role of bone marrow microenvironment and in particular of bone marrow stromal in anti-myeloma immune response
Authors: Cinzia Fionda
Affiliation: Department of Molecular Medicine, Sapienza University of Rome, 00161 Rome, Italy

Title: Bone marrow microenvironment in the pathogenesis of leukemia relapse: implications for immunotherapy
Authors: Nicola Stefano Fracchiolla
Affiliation: Fondazione Ca' Granda - Ospedale Maggiore Policlinico Milano, Milan, Italy

Back to TopTop